There isn't that much middle ground when it comes to Danish CNS specialty pharmaceutical company H Lundbeck A/S (OTCPK:HLUYY) - sell-side analysts either think it is an overvalued company with little chance of differentiating its new products in the market or they think it is an undervalued company that can drive significant value through advanced drug design methods that lead to products with better efficacy and/or safety profiles. With the recent clinical failure of desmoteplase and an unimpressive initial ramp for Brintellix and Abilify Maintena the bears are looking stronger of late, but I believe this risky specialty pharma company still has a few strong cards left to play.
An Okay Quarter, But Not A Game-Changer
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|